Medicare Enrolled
Dr. Lalita Pandit, M.D.
Hematology & Oncology · Fountain Valley, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Pandit from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Pandit?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Pandit
Dr. Lalita Pandit is a hematology & oncology specialist in Fountain Valley, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Pandit performed 74,760 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Pandit received a total of $39,685 from 95 pharmaceutical and/or device companies across 969 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Pandit is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 10% volume in CA
$39,685 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗74,760
Medicare services
Top 10% in CA for hematology & oncology
Not available
Unique patients (not deduplicated)
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
36,211 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
11,101 | $0 | $1 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
7,173 | $6 | $12 |
| Denosumab injection (Prolia/Xgeva) | 4,740 | $18 | $26 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,916 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,763 | $1 | $2 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,487 | $8 | $10 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,428 | $102 | $171 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,268 | $8 | $16 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
970 | $1 | $2 |
| Anti-nausea injection (ondansetron/Zofran) | 727 | $0 | $1 |
| Pegfilgrastim-apgf injection An injection of pegfilgrastim-apgf, a biosimilar medication. The dose specified is 0.5 mg. |
660 | $89 | $405 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
561 | $12 | $38 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
497 | $14 | $68 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
377 | $11 | $30 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
344 | $26 | $66 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
283 | $119 | $372 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
222 | $58 | $144 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
213 | $18 | $42 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
173 | $1 | $2 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
151 | $7 | $160 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
150 | $100 | $170 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
150 | $1 | $2 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
148 | $59 | $148 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 140 | $133 | $282 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
118 | $18 | $38 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
115 | $29 | $116 |
| Injection, lorazepam, 2 mg | 95 | $1 | $1 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
90 | $1 | $10 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
85 | $30 | $118 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
78 | $25 | $82 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
72 | $154 | $220 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
57 | $87 | $134 |
| New patient office visit, complex (60-74 min) | 52 | $184 | $315 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
50 | $109 | $202 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
44 | $20 | $42 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
26 | $143 | $237 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
25 | $51 | $123 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
51.9% high complexity
41.2% medium
6.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$39,685
Total received (2018-2024)
Avg $5,669/year across 7 years
Top 13% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
95
Companies
969
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,659
2023
$4,921
2022
$3,264
2021
$3,226
2020
$3,306
2019
$5,784
2018
$15,526
Payments by company (2024)
Janssen Biotech, Inc.
$286
Gilead Sciences, Inc.
$285
Incyte Corporation
$280
Amgen Inc.
$264
SOBI, INC
$248
PFIZER INC.
$195
Alexion Pharmaceuticals, Inc.
$194
Novartis Pharmaceuticals Corporation
$182
AstraZeneca Pharmaceuticals LP
$158
E.R. Squibb & Sons, L.L.C.
$151
JAZZ PHARMACEUTICALS INC.
$150
GENZYME CORPORATION
$148
Merck Sharp & Dohme LLC
$138
Celgene Corporation
$97
GlaxoSmithKline, LLC.
$94
Regeneron Healthcare Solutions, Inc.
$70
ImmunoGen, Inc.
$60
Takeda Pharmaceuticals U.S.A., Inc.
$55
Daiichi Sankyo Inc.
$51
Eisai Inc.
$41
EMD Serono, Inc.
$41
Rigel Pharmaceuticals, Inc.
$40
Deciphera Pharmaceuticals Inc.
$36
Stemline Therapeutics Inc.
$36
Organon Llc
$35
TerSera Therapeutics LLC
$35
Exelixis Inc.
$33
Lilly USA, LLC
$31
TAIHO ONCOLOGY, INC.
$31
PharmaEssentia USA Corporation
$29
Aveo Pharmaceuticals, Inc.
$26
Spectrum Pharmaceuticals Inc.
$24
Genentech USA, Inc.
$23
Coherus Biosciences Inc.
$23
BeiGene USA, Inc.
$21
ADC Therapeutics America, Inc.
$17
Chiesi USA, Inc.
$17
SERVIER PHARMACEUTICALS LLC
$13
Top 3 companies account for 23.2% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$7,765
Merck Sharp & Dohme Corporation
$7,188
Seattle Genetics, Inc.
$2,370
Amgen Inc.
$1,935
E.R. Squibb & Sons, L.L.C.
$1,602
Janssen Biotech, Inc.
$1,409
AstraZeneca Pharmaceuticals LP
$1,234
Incyte Corporation
$1,226
Takeda Pharmaceuticals U.S.A., Inc.
$936
PFIZER INC.
$912
GENZYME CORPORATION
$818
Merck Sharp & Dohme LLC
$651
Genentech USA, Inc.
$615
Gilead Sciences, Inc.
$585
GlaxoSmithKline, LLC.
$553
Celgene Corporation
$508
Seagen Inc.
$467
Astellas Pharma US Inc
$456
Eisai Inc.
$428
Lilly USA, LLC
$404
SOBI, INC
$376
Puma Biotechnology, Inc.
$324
Alexion Pharmaceuticals, Inc.
$312
Karyopharm Therapeutics Inc.
$310
Foundation Medicine, Inc.
$304
EMD Serono, Inc.
$277
Daiichi Sankyo Inc.
$270
JAZZ PHARMACEUTICALS INC.
$257
Regeneron Healthcare Solutions, Inc.
$245
Boehringer Ingelheim Pharmaceuticals, Inc.
$240
AVEO Pharmaceuticals, Inc.
$226
Pharmacyclics LLC, An AbbVie Company
$223
BeiGene USA, Inc.
$213
Rigel Pharmaceuticals, Inc.
$209
Organon LLC
$192
Kite Pharma, Inc.
$170
Ipsen Biopharmaceuticals, Inc
$168
Bayer HealthCare Pharmaceuticals Inc.
$168
TerSera Therapeutics LLC
$155
AMAG Pharmaceuticals, Inc.
$139
ADC Therapeutics America, Inc.
$138
MorphoSys, US Inc.
$125
Myovant Sciences Inc.
$121
Teva Pharmaceuticals USA, Inc.
$116
TESARO, Inc.
$114
EISAI INC.
$108
SANOFI-AVENTIS U.S. LLC
$100
Janssen Scientific Affairs, LLC
$99
Deciphera Pharmaceuticals Inc.
$81
AbbVie Inc.
$76
AbbVie, Inc.
$74
ARRAY BIOPHARMA INC
$72
Spectrum Pharmaceuticals Inc.
$71
Stemline Therapeutics Inc.
$70
Epizyme, Inc.,
$68
Blueprint Medicines Corporation
$63
Bayer Healthcare Pharmaceuticals Inc.
$61
Exelixis Inc.
$61
ImmunoGen, Inc.
$60
Taiho Oncology, Inc.
$57
TAIHO ONCOLOGY, INC.
$54
Otsuka America Pharmaceutical, Inc.
$54
Mylan Institutional Inc.
$49
Heron Therapeutics, Inc.
$48
Octapharma USA, Inc.
$45
Sumitomo Pharma America, Inc.
$45
Janssen Pharmaceuticals, Inc
$44
Coherus Biosciences Inc.
$44
Pharmacyclics LLC, an AbbVie Company
$44
Aurobindo Pharma USA, Inc.
$44
Clovis Oncology, Inc.
$41
PUMA BIOTECHNOLOGY, INC.
$41
Helsinn Therapeutics (U.S.), Inc.
$40
Organon Llc
$35
SERVIER PHARMACEUTICALS LLC
$34
Global Blood Therapeutics, Inc.
$33
MEDIVATION FIELD SOLUTIONS LLC
$30
GE HealthCare
$30
Kyowa Kirin, Inc.
$30
PharmaEssentia USA Corporation
$29
Sobi, Inc
$27
Aveo Pharmaceuticals, Inc.
$26
APO-PHARMA USA, INC.
$26
CTI BioPharma Corp.
$25
Novo Nordisk Inc
$22
Acceleron Pharma, Inc.
$22
RECORDATI_RARE_DISEASES_INC.
$21
Lexicon Pharmaceuticals, Inc.
$20
Acrotech Biopharma Inc.
$19
TOLMAR Pharmaceuticals, Inc.
$18
Partner Therapeutics, Inc.
$18
Chiesi USA, Inc.
$17
INSYS Therapeutics Inc
$17
Verastem, Inc.
$12
Dova Pharmaceuticals
$11
Top 3 companies account for 43.7% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · ALIMTA · ALUNBRIG · AYVAKIT · Alecensa · Avastin · BAVENCIO · BELEODAQ · BENDEKA · BESPONSA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABOMETYX · CALQUENCE · CYRAMZA · Cabometyx · Copiktra · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · ELZONRIS · EMPLICITI · ENHERTU · EPKINLY · ERBITUX · ERLEADA · EVENITY · EXKIVITY · Enhertu · Erleada · Esperoct · FERAHEME · FERRIPROX · FOTIVDA · FOUNDATIONONE · FRUZAQLA · FULPHILA · Fabhalta · Folotyn · Fulphila · GAMIFANT · GAZYVA · GILOTRIF · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Leukine · Lonsurf · MEKINIST · MONJUVI · MVASI · MYLOTARG · NERLYNX · NEXPLANON · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OJJAARA · ONTRUZANT · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · Padcev · Perjeta · Polivy · Pomalyst · Poteligeo · Prolia · QINLOCK · Quzyttir · REBLOZYL · ROLVEDON · RYBREVANT · RYDAPT · Reblozyl · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SHINGRIX · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUSTOL · SUTENT · SYLVANT · SYNDROS · Stivarga · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TUKYSA · Tavalisse · Tecentriq · Tibsovo · Trodelvy · Truxima · ULTOMIRIS · Udenyca · Ultomiris · VARUBI · VENCLEXTA · VERZENIO · VYXEOS · Vectibix · Venclexta · Vonjo · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XARELTO · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · ZYTIGA · Zoladex
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
208
County median income
$113,702
Nearest hospital to ZIP centroid (approximate)
UCI HEALTH - FOUNTAIN VALLEY
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Pandit is a mixed practice specialist, with above-average Medicare volume (top 10% in CA), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Pandit experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Pandit performed 36,211 iron infusion (feraheme) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Pandit receive payments from pharmaceutical companies?
Yes. Dr. Pandit received a total of $39,685 from 95 companies across 969 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Pandit's costs compare to other hematology & oncology specialists in Fountain Valley?
Dr. Pandit's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Pandit) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Fountain Valley
Browse hematology & oncology specialists in Fountain Valley ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Merck Sharp & Dohme Corporation Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme Corporation.
By company
Seattle Genetics, Inc. Payments to Doctors
See all physicians who received payments from Seattle Genetics, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology